The European Medicines Agency is taking steps to rethink how certain high-need medicines reach patients, with a new concept paper proposing a more flexible, evidence-based pathway for cancer therapies. While the focus is paediatric oncology, the implications may extend far beyond cancer, raising questions about whether similar approaches could eventually support the development of psychedelic treatments.

The “Weight of Evidence” Model

Published last month, the EMA’s concept paper outlines plans for a reflection paper on how “proof-of-concept” data should be used to guide early-stage drug development. At its core is a shift away from rigid data requirements toward a “weight of evidence” model, where regulators assess the totality of available data, including non-clinical studies, early clinical signals, and biological rationale.

This approach is already gaining traction in oncology, particularly in paediatric settings where patient populations are small and traditional large-scale trials are often unfeasible. In such cases, regulators are increasingly willing to rely on mechanistic understanding and preclinical evidence to justify moving into clinical trials earlier, provided there is a strong scientific rationale and unmet medical need.

The EMA’s concept paper emphasises that development decisions should be grounded in several key domains, including mechanism of action, disease biology, pharmacology, and safety, as well as the broader clinical context. Rather than requiring exhaustive datasets upfront, the agency is signalling openness to iterative development, where evidence is built progressively and regulatory decisions evolve alongside the data.

For the psychedelics field, this raises a clear question: could a similar framework accelerate the path to approval?

A shift toward mechanism-of-action–based regulation in psychedelics could, in theory, reduce the need to pursue separate approvals for each diagnostic category, such as depression or PTSD, by anchoring use to a shared underlying biology.

If regulators accept that psychedelic therapies exert their primary effect through defined pathways, for example 5-HT2A receptor activation leading to increased neuroplasticity and network-level brain changes, then the relevant treatment population could be framed around patients exhibiting that dysfunction rather than a specific DSM label. In this model, a single approval could cover multiple conditions where the same mechanism is implicated, provided there is sufficient evidence linking that pathway to clinical benefit across those populations.

This would shift development away from duplicative, indication-by-indication trials toward demonstrating consistent mechanistic effects and reproducible outcomes in biologically defined subgroups.

There are other parallels between the regulatory paths described in the paper and psychedelics. Psychedelic therapies are often being developed for conditions where unmet need remains high and patient populations can be difficult to study using conventional trial designs. Like paediatric oncology, these indications may benefit from more flexible approaches that incorporate multiple forms of evidence.

However, important differences remain.

Oncology drug development is underpinned by well-established biological models and biomarkers, allowing regulators to link mechanism of action to clinical outcomes with a relatively high degree of confidence. In contrast, the mechanisms underlying psychedelic therapies are still being defined, spanning pharmacological effects, neural network changes, and the subjective therapeutic experience itself.

The EMA’s framework places significant weight on the relevance and reliability of non-clinical models, an area where psychedelics currently face limitations. Translating findings from animal studies to complex psychiatric outcomes in humans remains a challenge, and there is no widely accepted biomarker that can serve as a proxy for therapeutic response.

Endpoints also differ. Cancer trials can rely on objective measures such as tumour progression or survival, whereas psychedelic studies typically depend on subjective scales and patient-reported outcomes. This makes it more difficult to integrate different sources of evidence into a unified regulatory decision.

Even so, the direction of travel is notable. By formalising a weight-of-evidence approach and emphasising mechanism-driven development, the EMA is signalling greater flexibility in how innovative therapies are assessed. If these principles are applied more broadly across therapeutic areas, they could eventually lower some of the structural barriers facing psychedelic drug development.

For now, the concept paper remains focused on oncology, and significant scientific and regulatory hurdles would need to be addressed before such a model could be extended to psychedelics. But as regulators continue to adapt to emerging forms of medicine, the boundaries between therapeutic areas may become less rigid.

In that context, the EMA’s latest move may not just reshape cancer drug development, but also offer an early glimpse of how the next generation of psychiatric treatments could be evaluated.

Picture: EMA headquarters in Amsterdam. Courtesy of EMA.

A study from the RAND Corporation has revealed a significant gap between the growing political momentum for psychedelic reform and actual US public opinion. While states like Oregon and Colorado have already moved toward regulated access, the majority of the American public remains cautious, particularly regarding synthetic substances like MDMA and LSD.

Psilocybin, The Preferred Choice

The 2025 RAND Psychedelics Survey found that psilocybin, often referred to as “magic mushrooms,” enjoys the highest level of support among psychedelics, with 23.1% of US adults backing its legalisation.

Interestingly, researchers noted that current support for psilocybin mirrors the public sentiment for cannabis in the mid-1990s, which was the period immediately preceding the first wave of state-level medical marijuana laws. For context, support for legal cannabis today stands at 64.6%. Whether psilocybin will follow this same exponential trajectory toward mainstream acceptance remains a central question for the psychedelics space.

Ambivalence Towards MDMA and LSD

Despite high-profile clinical trials and FDA-track research, synthetic psychedelics and empathogens face a much steeper climb in the face of public opinion.

Only 9.2% of respondents said they support MDMA for legal use. Support for LSD sits slightly higher at 9.9%, and more than three-quarters of Americans believe that both MDMA and LSD should remain illegal.

The report suggests that the public differentiates between “natural” and “synthetic” substances, showing a positive bias towards fungi-based medicines against lab-synthesised compounds.

Medical-First

The study highlights that support is not “all or nothing.” Even among those who oppose broad legalisation, there is significant support for therapeutic use.

Addressing mental or physical health conditions was the most cited reason for allowing legal access across all three substances: psilocybin (29.7%), LSD (22.7%), and MDMA (18.4%).

Respondents also showed support for taking psychedelics in a supervised setting. When asked how adults should access these medicines, the most endorsed model was at a medical facility under professional supervision (48.5% for psilocybin).

The Experience Gap

Personal experience remains a powerful driver of opinion. Among individuals who have actually used psilocybin, support for legalisation jumps to 61.6%. This follows the trend seen in the cannabis sector, where 80% of lifetime users support its legal status.

As the UK and Europe look to the US for regulatory cues, these data serve as a sobering reminder: while the “psychedelic renaissance” is well-underway in research labs and state legislatures, winning over the general public will require a sustained focus on medical safety and controlled environments, as well as clear communication on mainstream channels.

The RAND Corporation is a non-profit, non-partisan policy think tank known for its strict peer-review processes and a history of informing complex national security and health policies.

Illustration made using generative AI tools.

This article was written by Dr. Jenya Antonova, head of Compass Strategy and Research Inc., as part of Psychedelic Health’s op-ed program. To submit article ideas, please email news@psychedelichealth.co.uk

The psychedelic sector stands at a critical point. Clinical trials suggest meaningful benefits in depressive, anxiety-, trauma-related, and substance use disorders—conditions marked by substantial morbidity, diminished quality of life, and impaired social and occupational functioning.

Psychedelic treatments aim to improve not only symptoms, but how people think, feel, relate, and function in the world. In other words, they aim to improve health in its fullest sense. Public narratives speak of great potential. Investors anticipate scale.

Yet effective long-term integration into healthcare systems will be driven not by enthusiasm or early efficacy signals alone. For that, psychedelic therapies must demonstrate measurable safety and improvements in health in a way that satisfies regulators, health technology assessment bodies, policymakers, clinicians, and patients.

Health is a very complex construct. It is lived and experienced by each of us uniquely. And that lived experience must be measured. This is not merely a philosophical argument—it encapsulates the methodological and practical aspects of how lived experiences are measured in clinical trials.

In some therapeutic areas, like oncology, infectious diseases, diabetes, and endocrine autoimmune conditions, objective laboratory values, imaging, or physiological assessments can assess treatment response. In contrast, depressive, anxiety-, trauma-related, and substance-use disorders lack validated objective endpoints that confirm recovery.

Therefore, the assessment of risks and benefits of psychedelic medicine will ultimately rest on how convincingly it translates subjective assessment of well-being into rigorous patient experience data that matter to all stakeholders. 

However, different stakeholders interpret patient experience data through different lenses.

Assessing Effects: Clinically Meaningful vs. Statistically Significant 

Regulators determine whether substantial evidence of effectiveness and acceptable safety warrant authorization for use in humans. In the United States, the FDA’s Patient-Focused Drug Development framework makes clear that clinical outcome assessments used to support labeling claims must capture outcomes that are meaningful to patients—specifically how patients feel and function.

The instrument for clinical outcome assessment must be fit for purpose, with demonstrated validity, reliability, and responsiveness in the target population. In Europe, the EMA reflection paper on the use of health-related quality-of-life measures in the evaluation of medicinal products underscores that patient-reported outcomes must be methodologically sound and clinically interpretable to inform regulatory decision-making. Beyond reliability and validity, scoring must be clearly interpretable to ensure that demonstrated effects are clinically meaningful, not merely statistically significant.

Historically, regulatory objectives around patient experience data have centered on labeling. Yet comprehensive patient experience data can also enhance the evidentiary robustness of the entire submission. It includes evidence of holistic treatment effects, psychiatric safety, durability of benefit, the potential influence of functional unblinding and expectation bias—considerations that featured prominently in the FDA’s 2024 review of MDMA-assisted therapy for PTSD.

From Approval to Rollout and Patient Uptake

Once regulatory approval is granted, the next critical milestone is reimbursement. The health technology assessment (HTA) agencies worldwide place significant weight on patient experience data, though their approaches vary.

The German AMNOG legislation and the EU Joint Clinical Assessment framework require patient-relevant outcomes, including morbidity and health-related quality of life. Other agencies such as TLV (Sweden), ZIN (the Netherlands), NoMA (Norway), SMC (Scotland), NCPE (Ireland), HAS (France), and NICE (the UK) evaluate patient experience data within their clinical or economic appraisals.

Health-utility estimates used in cost-utility analyses are typically derived from patient experience data. All HTA bodies demand that patient experience data be of high methodological rigor, consistent with standards established by regulatory agencies. 

Along with the HTA agencies, policy makers will decide whether psychedelic medicine remains niche and tightly constrained, or becomes responsibly integrated into mainstream care. Their decisions will hinge on whether the field can provide rigorous evidence of long-term safety, durability of effect, real-world functional recovery, and abuse potential—areas for which long-term patient experience data will be critical.

Approval, however, does not guarantee wide uptake. Ultimately, patients decide whether to pursue a therapy. Patients want to understand not only “Does it work?” but also “What will it feel like? How will it change my daily life? What challenges might I face?” 

Here, credible data on direct lived experiences can replace anecdote and media narratives, enabling patients to make well-informed decisions grounded in what matters to them most.

Clinicians bridge the gap between clinical trial data and the patient taking the treatment. In psychedelic medicine, they not only prescribe treatments, determine dosing, but also facilitate and monitor sessions, advise patients, and monitor the effect of treatment. Rigorous patient experience data enables clinicians to merge evidence-based decision-making with a patient-centered approach.

Understanding Patient Experience Data

How, then, can patient experience data be demonstrated in practice?

The most common and most influential approach is for Phase 3 to generate evidence-based instruments for clinical outcome assessment, which include clinician-reported outcomes, and patient-reported outcomes. These instruments can—and often do—support primary, secondary, or exploratory endpoints rendering completeness to the risk-benefit assessment. 

Qualitative research offers a scientific framework for systematically capturing patients’ lived experiences. Qualitative evidence is a must for establishing content validity of instruments for patient-reported outcomes and clinician-reported outcomes that support clinical trial endpoints. 

In-trial interviews can take clinical trial data to the next level: contextualize quantitative findings, deepen understanding of patient experience with the treatment, and generate critical evidence for the interpretation of treatment effect. In psychedelic medicine, qualitative insights can be particularly powerful when systematically collected and analyzed.

Patient preference research represents another powerful tool. Preference studies can quantify how patients weigh different treatment attributes—safety, efficacy, overall treatment experience, and long-term outcomes. Understanding of patient trade-offs can inform regulatory, reimbursement, policy decision-making and clinical counseling.

What does it all mean for the strategy?

The central lesson we have learned from other therapeutic areas, which applies acutely to psychedelics, is that patient experience data must be intentional. It requires early planning, validated instruments, clear endpoint hierarchies, and alignment with regulatory and HTA expectations.

The lack of comprehensive patient experience data can inhibit regulatory and HTA reviews and result in suboptimal access outcomes. Yet launching patient experience data strategy at Phase 3 is likely too late.

Phase 3 are confirmatory trials. By then, the instruments must be validated, endpoints pre-specified, statistical power estimated, and clinically meaningful change established. If these decisions are not pre-determined, Phase 3 carries avoidable risks that are costly and highly visible.

Phase 2 should therefore serve a dual purpose: to explore efficacy and to establish the patient experience data framework. This includes validating clinical outcome assessments, testing their performance in the target population, and defining thresholds for meaningful change that can be carried forward into confirmatory trials. Therefore, sponsors should start planning patient experience data strategy very early. 

For investors, an early patient experience data strategy can signal strategic maturity, foresight into the future regulatory and HTA requirements, and understanding of what will drive the value in a field subjected to intense public scrutiny and regulatory attention. 

As psychedelic therapies confront heightened scrutiny, they must show their ability to transform patient lives and improve their functioning in society. For that, rigorous patient experience data is not optional. It is a winning card.

Illustration made using generative AI tools.